Results 51 to 60 of about 19,553 (185)
Molecular and Cellular Endocrinology, 2019 The family of G protein-coupled receptors (GPCRs) is the largest class of membrane proteins and an important drug target due to their role in many (patho)physiological processes. Besides small molecules, GPCRs can be targeted by biologicals including antibodies and antibody fragments.
De Groof, Timo +3 more
openaire +2 more sources
Novel Human Tenascin-C Function-Blocking Camel Single Domain Nanobodies
Frontiers in Immunology, 2021 The extracellular matrix (ECM) molecule Tenascin-C (TNC) is well-known to promote tumor progression by multiple mechanisms. However, reliable TNC detection in tissues of tumor banks remains limited.
Sayda Dhaouadi +18 more
doaj +1 more source
Frontiers in Bioengineering and Biotechnology, 2022 Nanobodies® (VHH antibodies), are small peptides that represent the antigen binding domain, VHH of unique single domain antibodies (heavy chain only antibodies, HcAb) derived from camelids.
Marco Pitino +4 more
doaj +1 more source
Cloning and characterisation of nanobodies against the coat protein of Zucchini yellow mosaic virus
Plant Protection Science, 2018 Zucchini yellow mosaic virus (ZYMV), in the family Potyviridae, causes an economically important disease. Antibodies are valuable reagents for diagnostic assays to rapidly detect viral infection.
Adel M. Zakri +8 more
doaj +1 more source
Recombinant expression of nanobodies and nanobody-derived immunoreagents
Protein Expression and Purification, 2020 Antibody fragments for which the sequence is available are suitable for straightforward engineering and expression in both eukaryotic and prokaryotic systems. When produced as fusions with convenient tags, they become reagents which pair their selective binding capacity to an orthogonal function.
openaire +3 more sources
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics [PDF]
Frontiers in Immunology, 2017 Monoclonal antibodies have revolutionized cancer therapy. However, delivery to tumor cells in vivo is hampered by the large size (150 kDa) of conventional antibodies. The minimal target recognition module of a conventional antibody is composed of two non-covalently associated variable domains (VH and VL).
Peter Bannas +2 more
openaire +3 more sources
Nanobodies in cell-mediated immunotherapy: On the road to fight cancer
Frontiers in Immunology, 2023 The immune system is essential in recognizing and eliminating tumor cells. The unique characteristics of the tumor microenvironment (TME), such as heterogeneity, reduced blood flow, hypoxia, and acidity, can reduce the efficacy of cell-mediated immunity.
Amirhosein Maali +9 more
doaj +1 more source
Visual and High-Efficiency Secretion of SARS-CoV-2 Nanobodies with Escherichia coli
BiomoleculesNanobodies have gained attention as potential therapeutic and diagnostic agents for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to their ability to bind and neutralize the virus.
Shuai Zhao +8 more
doaj +1 more source
A toolbox of nanobodies developed and validated for use as intrabodies and nanoscale immunolabels in mammalian brain neurons. [PDF]
, 2019 Nanobodies (nAbs) are small, minimal antibodies that have distinct attributes that make them uniquely suited for certain biomedical research, diagnostic and therapeutic applications.
Dong, Jie-Xian +11 more
core
, 2019 The nuclear pore complex (NPC) is one of the largest and most complex protein assemblies in the cell and, among other functions, serves as the gatekeeper of nucleocytoplasmic transport.
Auer, A. +10 more
core +1 more source